Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients

<div>The PSA response to enzalutamide treatment was concluded from all enrolled patients with different expression patterns of CXCR7.</div>

Disease Markers

Figure 2: Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients 